Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jul 27:9:911393.
doi: 10.3389/fcvm.2022.911393. eCollection 2022.

Contemporary survival and anticoagulation of patients with atrial fibrillation: A community based cohort study in China

Yong Wei  1 , Qingye Zeng  1 , Lidong Cai  1 , Xingjie Wang  2 , Bin Wang  3 , Chaoying Shen  4 , Chao Li  5 , Caihong Wang  6 , Yahong Shen  7 , Shunhong Yang  8 , Xiaoyu Wu  1 , Yan Liu  1 , Juan Xu  1 , Xiaofeng Lu  1 , Songwen Chen  1 , Genqing Zhou  1 , Shaowen Liu  1
Affiliations

Contemporary survival and anticoagulation of patients with atrial fibrillation: A community based cohort study in China

Yong Wei et al. Front Cardiovasc Med. .

Abstract

Backgrounds: The understanding of death in patients with atrial fibrillation (AF) in China is limited. This study aimed to assess the contemporary survival of AF patients in China and to explore risk factors for deaths.

Methods: This was a prospective community-based cohort study including 559 AF patients, who were followed-up from July 2015 to December 2020.

Results: During 66-month follow-up, there were 200 deaths (56.5% cardiovascular, 40.0% non-cardiovascular, and 3.5% unknown causes) among 559 AF patients with the median age of 76 years. The top three causes of death were heart failure (33.0%), ischemic stroke (17.0%) and cancer (16.5%). Multivariate Cox regression analysis indicated baseline variables positively associated with all-cause death were age (HR: 1.10, 95% CI: 1.08-1.13), AF subtype (HR: 1.37, 95% CI: 1.08-1.73), prior myocardial infarction (HR: 3.40, 95% CI: 1.48-7.78), previous tumor (HR: 2.61, 95% CI: 1.37-4.98), hypoglycemic therapy at baseline (HR: 1.81, 95% CI: 1.13-2.91), but body weight (HR: 0.98, 95% CI: 0.97-1.00) and use of calcium channel blocker (CCB) (HR: 0.62, 95% CI: 0.41-0.95) played a protective role to all-cause death. Of patients who were alive at the end of follow-up, 24.0% were on oral anticoagulants (OAC) alone, 4.5% on dual antithrombotic therapy, 33.1% on antiplatelet agents alone and 38.4% weren't on any antithrombotic medication.

Conclusion: Ischemic stroke still remains one of the leading causes of death and OAC is seriously underused in AF patients in China. Independent risk factors for death are age, AF subtype, previous tumor, prior myocardial infarction, hypoglycemic therapy, low body weight and no CCB use.

Clinical trial registration: http://www.chictr.org.cn/ (ChiCTR-ICR-15007036).

Keywords: anticoagulation; atrial fibrillation; mortality; stroke; survival.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The handling editor declared a past co-authorship with one of the authors SL.

Figures

Figure 1
Figure 1
Survival of patients with atrial fibrillation.
Figure 2
Figure 2
Cumulative incidences of death for specific causes. CV, cardiovascular; NCV, non-cardiovascular.
Figure 3
Figure 3
Current status of antithrombotic treatment in patients with atrial fibrillation who were alive at the end of the follow-up.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomström-Lundqvist C, et al. . 2020 ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European association for cardio-thoracic surgery (EACTS): The task force for the diagnosis and management of atrial fibrillation of the European society of cardiology (ESC) developed with the special contribution of the European heart rhythm association (EHRA) of the ESC. Eur Heart J. (2021) 42:373–498. 10.1093/eurheartj/ehab648 - DOI - PubMed
    1. Wei Y, Xu J, Wu H, Zhou G, Chen S, Wang C, et al. . Survey of antithrombotic treatment in rural patients (>60 years) with atrial fibrillation in East China. Sci Rep. (2018) 8:6830. 10.1038/s41598-018-24878-y - DOI - PMC - PubMed
    1. Guo Y, Tian Y, Wang H, Si Q, Wang Y, Lip GYH. Prevalence, incidence, and lifetime risk of atrial fibrillation in China: new insights into the global burden of atrial fibrillation. Chest. (2015) 147:109–19. 10.1378/chest.14-0321 - DOI - PubMed
    1. Du X, Guo L, Xia S, Du J, Anderson C, Arima H, et al. . Atrial fibrillation prevalence, awareness and management in a nationwide survey of adults in China. Heart. (2021) 107:535–41. 10.1136/heartjnl-2020-317915 - DOI - PMC - PubMed
    1. Marijon E, Le Heuzey JY, Connolly S, Yang S, Pogue J, Brueckmann M, et al. . Causes of death and influencing factors in patients with atrial fibrillation: a competing-risk analysis from the randomized evaluation of long-term anticoagulant therapy study. Circulation. (2013) 128:2192–201. 10.1161/CIRCULATIONAHA.112.000491 - DOI - PubMed

LinkOut - more resources